Lv6
1940 积分 2022-10-25 加入
Recent Advances in Bioanalytical Methods for Quantification and Pharmacokinetic Analyses of Antibody–Drug Conjugates
18小时前
待确认
Best practices in the application of parallelism for biomarker assay validation
18小时前
待确认
Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation
19小时前
待确认
Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
19小时前
待确认
Screening Non-neutralizing Anti-idiotype Antibodies Against a Drug Candidate for Total Pharmacokinetic and Target Engagement Assay
20小时前
待确认
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
1个月前
已完结
Arvinas’s PROTACs pass first safety and PK analysis
1个月前
已完结
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
1个月前
已完结
Link between drug absorption solubility and permeability measurements in Caco-2 cells
1个月前
已完结
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
1个月前
已完结
皖公网安备34019202002308
